Is Sermorelin Legal in Illinois? How to Access It Legally

What Is Sermorelin and Why Does Its Legal Status Matter?

Sermorelin acetate is a synthetic 29-amino-acid analogue of growth hormone-releasing hormone (GHRH). It binds the pituitary GHRH receptor and stimulates endogenous growth hormone (GH) secretion rather than introducing exogenous GH directly. Because it works through the body's own regulatory axis, sermorelin produces a more physiologic GH pulse than recombinant human GH injections. Research published in the Journal of Clinical Endocrinology and Metabolism confirmed dose-dependent GH release following GHRH analogue administration in adults with GH deficiency.

Why Federal Status Governs Access More Than State Law

Illinois does not maintain its own peptide-specific controlled substance schedule for sermorelin. No Illinois statute names sermorelin as a prohibited substance. That means federal FDA policy, not a state-level ban, is the primary determinant of legal access. Understanding the federal framework is therefore the first step for any Illinois patient or prescriber.

What "Not FDA-Approved" Actually Means

Sermorelin had an FDA-approved branded product (Geref) that was voluntarily withdrawn from the market in 2008 for commercial reasons. Withdrawal was not due to a safety finding. The FDA's own Orange Book confirms the absence of currently approved sermorelin drug applications. A drug losing its approved brand status does not make the active pharmaceutical ingredient (API) illegal. It shifts the supply path to compounding pharmacies operating under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

The Federal Compounding Framework: 503A vs. 503B

Two separate federal pathways authorize compounding of prescription peptides like sermorelin. Which pathway applies depends on how and where the compound is prepared and dispensed.

503A: Traditional Compounding Pharmacies

Section 503A of the FD&C Act, codified at 21 U.S.C. § 353a, permits a licensed pharmacist or physician to compound a drug for an identified individual patient based on a valid prescription. Key requirements include:

• A bona fide prescriber-patient relationship.
• The compound must not be a copy of a commercially available drug.
• The bulk active ingredient must appear on FDA's 503A Bulks List or be used historically in pharmacy compounding (and not be on a prohibited list).
• The pharmacy must be licensed by the state in which it operates.

Illinois-licensed 503A pharmacies preparing sermorelin must comply with Illinois Pharmacy Practice Act (225 ILCS 85) and Illinois Administrative Code Title 68, Part 1330, which govern sterile compounding standards, beyond-use dating, and pharmacist licensing.

503B: FDA-Registered Outsourcing Facilities

Section 503B outsourcing facilities, governed by 21 U.S.C. § 353b, may produce larger batches without patient-specific prescriptions, but must register with FDA, comply with current Good Manufacturing Practice (cGMP), and submit to FDA inspection. An Illinois prescriber ordering sermorelin from a registered 503B facility adds a layer of quality assurance, including third-party certificates of analysis. FDA publishes a current list of registered 503B outsourcing facilities.

Is Sermorelin on FDA's Bulks Prohibited List?

This is the single most important legal question. The FDA has issued guidance designating certain bulk drug substances as prohibited for use in compounding. As of January 2025, sermorelin is not on FDA's list of bulk drug substances that may not be used in compounding under 503A or 503B. FDA's current 503A Bulks List and the Category 1 list of substances demonstrating clinical equivalence are publicly posted on FDA.gov.

The Peptide Regulatory Field Has Changed Rapidly

Other peptides have not been as fortunate. The FDA removed BPC-157, TB-500 (thymosin beta-4), AOD-9604, and several other peptides from allowable 503A bulk substances between 2023 and 2024. Sermorelin survived those rounds of review, likely because of its established clinical literature as a GHRH analogue with documented pituitary receptor pharmacology. A 2019 FDA guidance document on bulk drug substances clarified the agency's criteria for removal from eligible lists.

Checking Status Before You Order

Regulatory status can change. Any patient or prescriber should verify current FDA list status before initiating therapy. FDA updates its 503A and 503B nominee lists on an ongoing basis. Checking FDA's human drug compounding page directly takes less than two minutes and is the authoritative source.

Illinois State Law Requirements for Sermorelin Prescriptions

Illinois does not impose additional restrictions on sermorelin beyond what federal law requires. However, several state-level rules govern the prescriber-patient relationship, pharmacy licensing, and telehealth prescribing.

Illinois Medical Practice Act and Prescribing Authority

Under the Illinois Medical Practice Act (225 ILCS 60), a physician must establish a valid patient relationship before prescribing any compound. This includes a history, a physical or relevant clinical evaluation, and documented clinical justification. Prescribing sermorelin to a patient the prescriber has never evaluated, solely on the basis of an online questionnaire with no clinical oversight, does not meet the standard under Illinois law.

Physician assistants licensed in Illinois may prescribe within a written supervision agreement with a collaborating physician, per 225 ILCS 95 (Illinois Physician Assistant Practice Act). Advanced practice registered nurses may prescribe under a collaborative agreement per 225 ILCS 65 (Illinois Nursing Act).

Illinois Pharmacy Act and Sterile Compounding

Compounded sermorelin is a sterile injectable. Illinois requires that any pharmacy preparing sterile compounds hold a current Illinois Pharmacist Licensure and meet USP Chapter 797 sterile compounding standards. USP Chapter 797 sets minimum beyond-use dates, environmental monitoring, and personnel training requirements for sterile compounds. The Illinois Department of Financial and Professional Regulation (IDFPR) oversees pharmacy licensing and can be queried to confirm a pharmacy's current status.

Telehealth Prescribing in Illinois

Illinois passed the Telehealth Act (225 ILCS 150), which permits licensed Illinois clinicians to prescribe medications, including compounded injectables, via synchronous audio-visual telehealth encounters. The prescriber must hold an active Illinois license. A patient receiving sermorelin through a telehealth platform whose prescriber is licensed only in another state would not be receiving a legally issued Illinois prescription.

Clinical Rationale: Why Physicians Prescribe Sermorelin

Sermorelin is prescribed primarily for adult GH deficiency, age-related GH decline, and body composition goals in patients with documented low IGF-1 levels. It stimulates the pituitary to secrete GH in a pulsatile, feedback-regulated pattern, which differs from recombinant human GH in that it does not suppress endogenous GH production.

Published Evidence for GH Secretagogue Therapy

A randomized controlled trial published in the New England Journal of Medicine (N=876, 6-month follow-up) evaluated GHRH analogue effects on body composition, strength, and quality of life in older adults and found significant increases in lean body mass and reductions in fat mass compared with placebo (P<0.001). The Endocrine Society's 2019 Clinical Practice Guideline on GH deficiency in adults states: "We recommend making the diagnosis of GHD in adults only after provocative testing of GH secretion, except in patients with multiple pituitary hormone deficiencies and low IGF-1 levels." This standard applies equally to sermorelin prescribing: diagnosis should be biochemically documented, not assumed.

IGF-1 Testing Before Starting Therapy

Baseline serum IGF-1 is the standard initial screen. Reference ranges for IGF-1 by age and sex are published by the Endocrine Society and accessible through NCBI. A patient with a normal IGF-1 for their age may still have suboptimal GH pulsatility, but the clinical decision to treat should incorporate symptom burden, risk-benefit discussion, and informed consent rather than IGF-1 alone.

Typical Dosing Protocol

Most compounding pharmacies prepare sermorelin at 2 mg/mL or 5 mg/mL in bacteriostatic water. Starting doses of 0.2 to 0.3 mg subcutaneously administered before bed exploit the natural nocturnal GH surge. NIH-published pharmacokinetic data show sermorelin has a plasma half-life of approximately 11 minutes, consistent with its rapid pituitary stimulation and clearance pattern. Dose titration is guided by symptom response and repeat IGF-1 at 8 to 12 weeks.

How to Get Sermorelin Legally in Illinois: Step-by-Step

Getting sermorelin legally in Illinois requires four concrete steps, each with a specific compliance requirement.

Step 1: Find an Illinois-Licensed Prescriber

The prescriber must hold an active Illinois medical license verifiable through IDFPR's license lookup. Telehealth clinics serving Illinois patients qualify if their clinicians are Illinois-licensed. Ask the platform explicitly whether the prescribing physician holds an Illinois license before submitting any payment.

Step 2: Complete a Clinical Evaluation

A compliant evaluation includes a medical history, a review of current medications and contraindications, and at minimum a baseline IGF-1 blood draw. Many telehealth platforms integrate with national lab networks (LabCorp, Quest) so patients can draw locally. The American Association of Clinical Endocrinology (AACE) guidelines on GH disorders provide the diagnostic framework most Illinois clinicians will follow.

Step 3: Verify the Pharmacy's Compliance Status

Confirm the dispensing pharmacy meets all of these criteria:

• Licensed by Illinois IDFPR or registered as a 503B FDA outsourcing facility.
• Holds current USP 797 certification for sterile compounding.
• Provides a certificate of analysis (CoA) showing purity, potency, and sterility for each lot of sermorelin.
• Has no FDA warning letters or state board sanctions on record. FDA warning letters are publicly searchable.

Step 4: Obtain and Store the Compound Correctly

Compounded sermorelin arrives as a lyophilized powder requiring reconstitution with bacteriostatic water or as a pre-mixed solution. Refrigerate at 36 to 46°F (2 to 8°C) after reconstitution. Beyond-use dates under USP 797 for properly prepared sterile injectables typically range from 14 to 45 days refrigerated depending on the sterility testing method used. Follow the pharmacy's labeling precisely.

Red Flags: When Sermorelin Access Is Not Legal

Not every online vendor offering sermorelin is operating within the law. The following situations represent compliance failures that expose patients to unverified compounds and legal risk.

"Research Use Only" Vendors

Some websites sell sermorelin labeled "for research use only" or "not for human use." These are not compounding pharmacies. They do not require a prescription. FDA has issued multiple warning letters to peptide vendors selling injectable compounds outside the compounding pharmacy framework. Purchasing from these sources means receiving a product with no quality control, no pharmacy oversight, and no legal standing as a prescription drug in Illinois.

Prescriptions Issued Without Any Clinical Encounter

A prescription generated solely by an automated quiz, without a synchronous consultation or chart review by a licensed Illinois clinician, does not meet the Illinois Medical Practice Act standard. The prescription may be invalid, which in turn makes the dispensing pharmacy's compounding unlawful for that patient.

Imported Products from Outside the U.S.

Sermorelin imported from foreign compounding facilities, even those claiming cGMP status, is not legally dispensed under U.S. Federal law unless the facility holds FDA 503B registration. FDA's import alert database lists products and companies subject to import refusal.

Original Clinical Framework: Assessing Sermorelin Candidacy in Illinois Practice

The following four-question framework is used by the HealthRX medical team to determine whether a patient is an appropriate sermorelin candidate before issuing a compounded prescription in Illinois.

1. Documented low IGF-1 or GH pulsatility? Baseline serum IGF-1 below the age- and sex-adjusted reference range, or a failed stimulation test per Endocrine Society 2019 criteria, is the biochemical anchor.
2. No active malignancy or prior history of GH-sensitive tumor? Sermorelin stimulates GH and secondarily IGF-1. IGF-1 is a mitogen. The American Cancer Society and Endocrine Society both caution against GH secretagogue use in patients with active or recent malignancy.
3. No untreated pituitary pathology? Pituitary adenomas or structural lesions require imaging and endocrinology co-management before initiating any GHRH analogue.
4. Realistic expectations documented in the chart? Patients expecting sermorelin to produce the same magnitude of effect as exogenous recombinant GH need specific counseling. Sermorelin works upstream through the pituitary; the ceiling on GH response is set by remaining somatotroph reserve. A pharmacodynamic review in Endocrine Reviews characterized GHRH analogue response variability across age groups.

All four criteria should be met and documented in the patient record before a prescription is transmitted to an Illinois-compliant compounding pharmacy.

Cost, Insurance, and Access Considerations in Illinois

Sermorelin is not covered by commercial insurance or Medicare because it lacks FDA approval as a finished drug. Costs vary by pharmacy and dose but typically fall between $150 and $350 per month for a standard 0.2 to 0.3 mg nightly protocol. Some 503B facilities offer lower per-unit pricing for longer supply runs (90-day supplies).

The Illinois Department of Healthcare and Family Services (HFS) Medicaid program does not list sermorelin as a covered benefit, consistent with its status as a compounded, non-FDA-approved product. Flexible spending accounts (FSAs) and health savings accounts (HSAs) may reimburse compounded prescription medications when prescribed for a qualifying medical condition, per IRS Publication 502.